Literature DB >> 32216516

Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis.

Andrew J Kinloch1, Matthew D Cascino2, Jian Dai3, Rene S Bermea4, Kichul Ko4, Margaret Vesselits1, Leonard L Dragone5, Nirit Mor Vaknin6, Maureen Legendre6, David M Markovitz6, Michael K Okoreeh1, Michael J Townsend7, Marcus R Clark1,4.   

Abstract

Entities:  

Keywords:  Vimentin; autoantibodies; lupus nephritis; prognosis; systemic lupus erythematosus

Mesh：

Substances：

Year:  2020        PMID： 32216516      PMCID： PMC7278023          DOI： 10.1177/0961203320913606

Source DB:  PubMed          Journal:  Lupus        ISSN： 0961-2033            Impact factor:   2.911


× No keyword cloud information.
  48 in total

1.  In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.

Authors:  Anthony Chang; Scott G Henderson; Daniel Brandt; Ni Liu; Riteesha Guttikonda; Christine Hsieh; Natasha Kaverina; Tammy O Utset; Shane M Meehan; Richard J Quigg; Eric Meffre; Marcus R Clark
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

2.  Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.

Authors:  Preeti Lal; Zheng Su; Cecile T J Holweg; Gregg J Silverman; Sergio Schwartzman; Ariella Kelman; Simon Read; Greg Spaniolo; John G Monroe; Timothy W Behrens; Michael J Townsend
Journal:  Arthritis Rheum       Date:  2011-12

3.  Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Authors:  Marie B Condon; Damien Ashby; Ruth J Pepper; H Terence Cook; Jeremy B Levy; Megan Griffith; Tom D Cairns; Liz Lightstone
Journal:  Ann Rheum Dis       Date:  2013-06-05       Impact factor: 19.103

4.  Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Authors:  Brad H Rovin; Richard Furie; Kevin Latinis; R John Looney; Fernando C Fervenza; Jorge Sanchez-Guerrero; Romeo Maciuca; David Zhang; Jay P Garg; Paul Brunetta; Gerald Appel
Journal:  Arthritis Rheum       Date:  2012-01-09

5.  Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.

Authors:  Holger Bang; Karl Egerer; Anke Gauliard; Kirsten Lüthke; Paul E Rudolph; Gert Fredenhagen; Wigbert Berg; Eugen Feist; Gerd-R Burmester
Journal:  Arthritis Rheum       Date:  2007-08

6.  Cytoskeleton antibodies in chronic active hepatitis, primary biliary cirrhosis, and alcoholic liver disease.

Authors:  P Kurki; A Miettinen; M Salaspuro; I Virtanen; S Stenman
Journal:  Hepatology       Date:  1983 May-Jun       Impact factor: 17.425

7.  dendextend: an R package for visualizing, adjusting and comparing trees of hierarchical clustering.

Authors:  Tal Galili
Journal:  Bioinformatics       Date:  2015-07-23       Impact factor: 6.937

8.  High-throughput proteomics reveal alarmins as amplifiers of tissue pathology and inflammation after spinal cord injury.

Authors:  Athanasios Didangelos; Michele Puglia; Michaela Iberl; Candela Sanchez-Bellot; Bernd Roschitzki; Elizabeth J Bradbury
Journal:  Sci Rep       Date:  2016-02-22       Impact factor: 4.379

9.  The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness.

Authors:  Borja Gracia-Tello; Amara Ezeonyeji; David Isenberg
Journal:  Lupus Sci Med       Date:  2017-02-02

10.  Involvement of the N-terminal polypeptide of vimentin in the formation of intermediate filaments.

Authors:  P Traub; C E Vorgias
Journal:  J Cell Sci       Date:  1983-09       Impact factor: 5.285
View more
  5 in total

1.  Specific in situ inflammatory states associate with progression to renal failure in lupus nephritis.

Authors:  Rebecca Abraham; Madeleine S Durkee; Junting Ai; Margaret Veselits; Gabriel Casella; Yuta Asano; Anthony Chang; Kichul Ko; Charles Oshinsky; Emily Peninger; Maryellen L Giger; Marcus R Clark
Journal:  J Clin Invest       Date:  2022-07-01       Impact factor: 19.456

2.  Generation of Monoclonal Antibodies Specific for Native LL37 and Citrullinated LL37 That Discriminate the Two LL37 Forms in the Skin and Circulation of Cutaneous/Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients.

Authors:  Roberto Lande; Raffaella Palazzo; Philippe Hammel; Immacolata Pietraforte; Isabelle Surbeck; Michel Gilliet; Carlo Chizzolini; Loredana Frasca
Journal:  Antibodies (Basel)       Date:  2020-05-11

Review 3.  Vimentin as a Multifaceted Player and Potential Therapeutic Target in Viral Infections.

Authors:  Irene Ramos; Konstantinos Stamatakis; Clara L Oeste; Dolores Pérez-Sala
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

4.  Machine Learning to Quantify In Situ Humoral Selection in Human Lupus Tubulointerstitial Inflammation.

Authors:  Andrew J Kinloch; Yuta Asano; Azam Mohsin; Carole Henry; Rebecca Abraham; Anthony Chang; Christine Labno; Patrick C Wilson; Marcus R Clark
Journal:  Front Immunol       Date:  2020-11-27       Impact factor: 7.561

Review 5.  Cellular aspects of the pathogenesis of lupus nephritis.

Authors:  Anthony Chang; Marcus R Clark; Kichul Ko
Journal:  Curr Opin Rheumatol       Date:  2021-03-01       Impact factor: 4.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.